Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, yielding high remission rates across leukemia and lymphoma. However, extending this success to solid tumors—representing more than 90% of all cancer cases—has proven significantly more challenging.¹ In the past five years, significant scientific advances have improved CAR design, trafficking, and persistence, while clinical trials have expanded rapidly across glioblastoma, ovarian cancer, lung cancer, and other difficult-to-treat tumors.
This article provides a clinically focused overview of the current evidence, biological barriers, innovations in CAR-T engineering, and emerging data shaping the future of CAR-T for solid tumors.
The FDA approval of CD19-directed CAR-T therapies marked a breakthrough in oncology, delivering durable remission even in relapsed/refractory hematologic cancers.² However, translating these outcomes to solid tumors has been hindered by tumor heterogeneity, immune suppression, antigen escape, and stiff physical barriers surrounding tumor tissue.³
Despite these obstacles, more than 700 CAR-T clinical trials targeting solid tumors are now active worldwide.⁴
The TME suppresses T-cell activity through mechanisms involving:
These factors reduce CAR-T cell persistence and cytotoxicity.⁵
Solid tumors have abnormal vasculature and dense extracellular matrix (ECM), preventing CAR-T infiltration.⁶
Unlike CD19, many solid tumor antigens (HER2, mesothelin, EGFR, GD2) are also expressed in healthy tissues, increasing the risk of on-target off-tumor toxicity.⁷
Solid tumors downregulate or modify antigens, leading to treatment failure.⁸
Fourth-generation CAR-T cells overexpress stimulatory cytokines (IL-12, IL-18), which enhance infiltration and overcome TME suppression.⁹
Examples:
Dual targeting reduces antigen escape and increases tumor specificity.¹⁰
Synthetic Notch receptors activate the CAR only in the presence of a “priming antigen,” improving precision.¹¹
Gene edits to knock out PD-1, TGF-β receptors, or exhaustion-related transcription factors have shown increased persistence and activity in tumor models.¹²
Engineered macrophages can degrade the ECM, present antigen, and reprogram the TME, showing promise in early-phase trials.¹³
Targets under investigation: EGFRvIII, IL13Rα2, HER2.
A landmark study using IL13Rα2-CAR-T showed transient regression and radiographic improvement in recurrent GBM.¹⁴
Mesothelin-directed CAR-T demonstrated safety and modest antitumor activity in Phase I trials.¹⁵
Dense stroma limits infiltration, but targets such as mesothelin and Claudin-18.2 are showing early signals of activity.¹⁶
EGFR-CAR-T and MUC1-CAR-T have shown encouraging responses in heavily pretreated NSCLC patients in early trials.¹⁷
GD2-CAR-T has demonstrated antitumor activity in neuroblastoma and sarcoma models.¹⁸
HER2-CAR-T–associated pulmonary toxicity in early trials highlighted the need for safer target selection.¹⁹
Less frequent than hematologic use, but still significant. Management follows similar protocols with tocilizumab and steroids.²⁰
Combining CAR-T with other therapies is proving essential:
Next-generation CAR-T platforms and rational combination strategies are steadily addressing the historical challenges of targeting solid tumors. Moving forward, CAR-T therapy is poised to become a realistic therapeutic option in select solid cancers—especially glioblastoma, ovarian, and pancreatic tumors—within the next decade.